12,153 results match your criteria Factor IX

Genetic Variants Associated with Mineral Metabolism Traits in Chronic Kidney Disease.

J Clin Endocrinol Metab 2022 May 19. Epub 2022 May 19.

Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.

Background And Objectives: Chronic kidney disease (CKD) causes multiple interrelated disturbances in mineral metabolism. Genetic studies in the general population have identified common genetic variants associated with circulating phosphate, calcium, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23). In this study we aimed to discover genetic variants associated with circulating mineral markers in Chronic Kidney Disease. Read More

View Article and Full-Text PDF

A Pretreatment with Isoorientin Attenuates Redox Disruption, Mitochondrial Impairment, and Inflammation Caused by Chlorpyrifos in a Dopaminergic Cell Line: Involvement of the Nrf2/HO-1 Axis.

Neurotox Res 2022 May 18. Epub 2022 May 18.

Grupo de Estudos Em Neuroquímica E Neurobiologia de Moléculas Bioativas, Departamento de Química, Universidade Federal de Mato Grosso (UFMT), Av. Fernando Corrêa da Costa, 2367, Cuiaba, Mato Grosso, CEP 78060-900, Brazil.

The C-glucosyl flavone isoorientin (ISO) is obtained by humans from the diet and exhibits several cytoprotective effects, as demonstrated in different experimental models. However, it was not previously shown whether ISO would be able to prevent mitochondrial impairment in cells exposed to a chemical stressor. Thus, we treated the human neuroblastoma SH-SY5Y cells with ISO (0. Read More

View Article and Full-Text PDF

Factor-guided diagnosis of coagulopathy associated with coumarin-contaminated synthetic cannabinoids: A case report.

Am J Emerg Med 2022 May 10. Epub 2022 May 10.

Department of Clinical Pharmacy, Methodist University Hospital, 1265 Union Ave, Memphis, TN 38104, United States of America; University of Tennessee Health Science Center, College of Pharmacy, 881 Madison Ave, Memphis, TN 38103, United States of America.

Contamination of synthetic cannabinoids with toxic coumarin derivatives known as superwarfarins can induce a persistent coagulopathy. In comparison to warfarin, these derivatives have prolonged half-lives and laboratory assays for detection are not readily available in clinical practice. To our knowledge, factor-guided diagnosis of coagulopathy secondary to coumarin-contaminated synthetic cannabinoids has not been described previously. Read More

View Article and Full-Text PDF

Riemerella anatipestifer T9SS Effector SspA Functions in Bacterial Virulence and Defending Natural Host Immunity.

Appl Environ Microbiol 2022 May 16:e0240921. Epub 2022 May 16.

Shanghai Veterinary Research Institutegrid.464410.3, Chinese Academy of Agricultural Sciences (CAAS), Shanghai, China.

Riemerella anatipestifer is a major pathogenic agent of duck septicemic and exudative diseases. Recent studies have shown that the R. anatipestifer type IX secretion system (T9SS) is a crucial factor in bacterial virulence. Read More

View Article and Full-Text PDF

Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.

Haemophilia 2022 May 16. Epub 2022 May 16.

Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Introduction: Perioperative dosing recommendations vary across Nordic haemophilia treatment centres (HTCs) for extended half-life (EHL) factor concentrates in haemophilia A/B (HA/HB) patients.

Aim: To summarise Nordic real-world surgical experiences with EHL recombinant factor VIII/IX Fc (rFVIIIFc/rFIXFc) fusion proteins using retrospective data from clinical records at four HTCs in Finland, Sweden and Norway.

Methods: Factor dosing and surgical outcomes were recorded from HA/HB patients who underwent surgery and were treated with rFVIIIFc/rFIXFc. Read More

View Article and Full-Text PDF

Engineering CRISPR/Cas9 for Multiplexed Recombinant Coagulation Factor Production.

Int J Mol Sci 2022 May 3;23(9). Epub 2022 May 3.

Department of Pediatrics, Division of Blood and Marrow Transplantation, MMC 366 Mayo, 8366A, 420 Delaware Street SE, Minneapolis, MN 55455, USA.

Current hemostatic agents are obtained from pooled plasma from multiple donors requiring costly pathogen screening and processing. Recombinant DNA-based production represents an engineering solution that could improve supply, uniformity, and safety. Current approaches are typically for single gene candidate peptides and often employ non-human cells. Read More

View Article and Full-Text PDF

Novel Multifaceted Roles for RNF213 Protein.

Int J Mol Sci 2022 Apr 19;23(9). Epub 2022 Apr 19.

Laboratory of Neurobiology, Neurology IX Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.

Ring Finger Protein 213 (RNF213), also known as Mysterin, is the major susceptibility factor for Moyamoya Arteriopathy (MA), a progressive cerebrovascular disorder that often leads to brain stroke in adults and children. Although several rare RNF213 polymorphisms have been reported, no major susceptibility variant has been identified to date in Caucasian patients, thus frustrating the attempts to identify putative therapeutic targets for MA treatment. For these reasons, the investigation of novel biochemical functions, substrates and unknown partners of RNF213 will help to unravel the pathogenic mechanisms of MA and will facilitate variant interpretations in a diagnostic context in the future. Read More

View Article and Full-Text PDF

Safety of intramuscular COVID-19 vaccination in patients with haemophilia.

Haemophilia 2022 May 13. Epub 2022 May 13.

Division of Haemostaseology, Medical Department I, University Hospital Leipzig, Leipzig, Germany.

Background: Guidelines recommend that patients with haemophilia should preferably receive vaccination subcutaneously. COVID-19 and other vaccines, however, are only licenced for intramuscular application.

Aims: To assess the safety of intramuscular COVID-19 vaccination in patients living with haemophilia. Read More

View Article and Full-Text PDF

Lung function, allergic sensitization and asthma in school-aged children after viral-coinfection bronchiolitis.

Sci Rep 2022 May 9;12(1):7552. Epub 2022 May 9.

Pediatrics Department, Severo Ochoa University Hospital. Leganés, Madrid, Spain.

Our main objective was to compare the lung function, the rate of allergic sensitization and the prevalence of asthma at 7-9 years in children hospitalized for bronchiolitis with viral coinfection versus single viral infection. Observational study in children with previous bronchiolitis and current age 7-9 years. Clinical data were collected. Read More

View Article and Full-Text PDF

The bleeding phenotype in people with non-severe hemophilia.

Blood Adv 2022 May 9. Epub 2022 May 9.

Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.

Detailed information on the onset, frequency and severity of bleeding in non-severe hemophilia is limited. We aimed to assess the bleeding phenotype of people with non-severe hemophilia, and to analyse the association between baseline factor VIII/IX levels and the joint bleeding rate. In the DYNAMO study, an international multicenter cohort, we included males with non-severe hemophilia (factor VIII/IX (FVIII/IX) 0. Read More

View Article and Full-Text PDF

A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.

Saudi J Biol Sci 2022 Apr 15;29(4):2072-2084. Epub 2022 Jan 15.

Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, 1988, Najran 61441, Saudi Arabia.

Genitourinary cancers comprise of a heterogenous group of cancers of which renal cell carcinoma, urothelial bladder carcinoma, and prostate adenocarcinoma are the most commonly encountered subtypes. A lot of research is ongoing using various strategies for exploration of novel biomarkers for genitourinary cancers. These biomarkers would not reduce the need for invasive diagnostic techniques but also could be used for early and accurate diagnosis to improve the clinical management required for the disease. Read More

View Article and Full-Text PDF

Characterization of Laboratory Coagulation Parameters and Risk Factors for Intraventricular Hemorrhage in Extremely Premature Neonates.

J Thromb Haemost 2022 May 7. Epub 2022 May 7.

Bleeding & Clotting Disorders Institute, Peoria, IL, USA.

Background: Extremely premature neonates have increased risk for bleeding, perhaps most devastating of which being intraventricular hemorrhage (IVH). Limited data are available for coagulation parameters in this vulnerable population.

Objectives: We conducted a prospective cohort study characterizing coagulation laboratory parameters in extremely premature neonates 23-30 weeks gestational age (GA) and determined coagulation parameters and clinical risk factors associated with IVH. Read More

View Article and Full-Text PDF

Molecular therapeutics of hemophilia A and B.

Expert Rev Hematol 2022 May 17:1-11. Epub 2022 May 17.

School of Medicine, University of Electronic Science and Technology of China, Sichuan, China.

Introduction: Hemophilia A (HA) or B (HB) is an X-linked recessive disorder caused by a defect in the factor VIII (FVIII) or factor IX (FIX) gene which leads to the dysfunction of blood coagulation. Protein replacement therapy (PRT) uses recombinant proteins and plasma-derived products, which incurs high cost and inconvenience requiring routine intravenous infusions and life-time treatment. Understanding of detailed molecular mechanisms on FVIII gene function could provide innovative solutions to amend this disorder. Read More

View Article and Full-Text PDF

Gene therapy - are we ready now?

Haemophilia 2022 May;28 Suppl 4:35-43

Coagulation Products Safety Supply and Access Committee, World Federation of Hemophilia, Montreal, Quebec, Canada.

Introduction: Haemophilia therapy has evolved from rudimentary transfusion-based approaches to an unprecedented level of innovation with glimmers of functional cure brought by gene therapy. After decades of misfires, gene therapy has normalized factor (F)VIII and factor (F)IX levels in some individuals in the long term. Several clinical programmes testing adeno-associated viral (AAV) vector gene therapy are approaching completion with imminent regulatory approvals. Read More

View Article and Full-Text PDF

Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022.

Haemophilia 2022 May;28 Suppl 4:93-102

Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium.

New treatment possibilities and modalities are now available globally for patients with haemophilia requiring surgery or invasive procedures. The first is the appropriate application of low-dose protocols of clotting factor concentrates (CFC) achieving adequate perioperative haemostasis in resources constraint environments. The increasing availability of CFC through humanitarian aid programs allows more invasive surgeries to be performed for which efficacy and safety data should be more widely collected and reported. Read More

View Article and Full-Text PDF

Therapeutic and technological advancements in haemophilia care: Quantum leaps forward.

Haemophilia 2022 May;28 Suppl 4:77-92

Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, Indiana, USA.

Introduction: Recent technological innovations in haemophilia have advanced at an astounding pace, including gene therapy programmes and bioengineered molecules for prophylaxis, products that reduce treatment burden through half-life extension, unique mechanisms of action, and subcutaneous administration. Additional technological advancements have emerged that are anticipated to further transform haemophilia care.

Aim: Review new and emerging haemophilia therapies, including replacement and bypassing products, digital applications, utilisation of big data, and personalised medicine. Read More

View Article and Full-Text PDF

Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China.

Haemophilia 2022 May;28 Suppl 4:111-118

Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, Georgia, USA.

Factor (F) VIII inhibitors develop in around 30% of previously untreated patients (PUPs) with severe haemophilia, to a lesser extend in moderate and mild haemophilia A and in up to 10% in severe haemophilia B. Diagnostic challenges and questions remain including access to high quality testing, the role for functional inhibitor testing and binding antibody testing, and the adaptations needed in the presence of non-factor replacement therapy. Despite significant gains in knowledge there are still many unanswered questions underlying the immunologic mechanisms of inhibitor development and tolerance. Read More

View Article and Full-Text PDF

Gene therapy: Practical aspects of implementation.

Haemophilia 2022 May;28 Suppl 4:44-52

Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.

The first wave of gene therapies for haemophilia submitted for regulatory review utilize a liver-directed approach in which a functional gene copy of factor VIII (FVIII) or factor IX (FIX) is packaged inside a recombinant adeno-associated viral vector (rAAV). Following a single treatment event, these particles are taken up into liver cells, where the rAAV uncoats and delivers the DNA to the nucleus of the cell, where genetic elements that accompany the gene allow for efficient expression and secretion of FVIII or FIX protein into the plasma. An immune response to the vector capsid has been manifest by elevations in common liver enzymes that must be diligently followed postinfusion for weeks and months afterward and if signs of toxicity appear, will trigger a course of immunosuppression. Read More

View Article and Full-Text PDF

Platelet Activation via Glycoprotein VI Initiates Thrombin Generation: A Potential Role for Platelet-Derived Factor IX?

Thromb Haemost 2022 May 5. Epub 2022 May 5.

Department of Platelet Pathophysiology, Synapse Research Institute, Maastricht, the Netherlands.

Collagen triggers coagulation via activation of factor (F) XII. In a platelet-rich environment, collagen can also trigger coagulation independently of FXII. We studied a novel mechanism of coagulation initiation via collagen-dependent platelet activation using thrombin generation (TG) in platelet-rich plasma. Read More

View Article and Full-Text PDF

Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.

Thromb Res 2022 Apr 26;214:76-81. Epub 2022 Apr 26.

Department of Pharmacy, University of Rochester Medical Center, 601 Elmwood Ave. Box 638, Rochester, NY 14642, USA; Department of Emergency Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave. Box 655, Rochester, NY 14642, USA. Electronic address:

Introduction: The purpose was to compare hemostatic efficacy rates for fixed- and variable-dose four-factor prothrombin complex concentrate (4F-PCC) for warfarin reversal.

Material And Methods: Retrospective study of patients with non-intracranial major bleeding or undergoing emergent surgery/procedure who received 4F-PCC for warfarin reversal from September 2013 through August 2020. Hemostatic efficacy at 48 h following fixed- or variable-dose 4F-PCC was evaluated using modified International Society on Thrombosis and Hemostasis (ISTH) criteria for major bleeding. Read More

View Article and Full-Text PDF

Monthly and quarterly correction factors for determining the mean annual radon concentration in the atmosphere of underground workplaces in Poland.

Environ Geochem Health 2022 Apr 30. Epub 2022 Apr 30.

Faculty of Geoengineering, Mining and Geology, Laboratory of Geology and Planetary Sciences, Wrocław University of Science and Technology, Wybrzeże S. Wyspiańskiego 27, 50-370, Wrocław, Poland.

The aimed of the work was estimated the value (level) of mean annual Rn activity concentration in an underground space based on monthly (k) and quarterly (k) correction factors. The calculations of factors were developed with the assumption that measurements will be conducted for at least 1 month or a quarter of a year. Radon monitoring to confirm the calculated values was carried out continuously from 2008 to 2019 and verification was made on real data obtained in 2020. Read More

View Article and Full-Text PDF

The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: a single center experience.

Pan Afr Med J 2022 14;41:126. Epub 2022 Feb 14.

Hemophilia Treatment Center and Bleeding Disorders, Hematology-Oncology Unit, Children's Hospital Rabat, Mohamed V University, Rabat, Morocco.

The emergence of anti-factor VIII and anti-factor IX antibodies in hemophilia A or B is the most serious complication of hemophilia. We aim to expose through a series of patient's data, collected between 02/2009 and 02/2016 in the pediatric service of university hospital of Rabat, Morocco, the epidemiological and clinical characteristics of these patients, and to highlight the therapeutic difficulties encountered during their treatment. Out of 120 hemophiliac patients, we included 22 hemophiliac patients (18. Read More

View Article and Full-Text PDF

Green Plasma has a Superior Hemostatic Profile Compared With Standard Color Plasma.

Am Surg 2022 Apr 27:31348221096571. Epub 2022 Apr 27.

Department of Surgery, 12340University of Texas Health Science Center, Houston, TX, USA.

Background: Limitations in available donors have dramatically reduced plasma availability over the past several decades, concurrent with increasing demand for some types of plasma. Plasma from female donors who are pregnant or taking oral contraceptives often has a green appearance, which frequently results in these units being discarded. This pilot study aimed to evaluate the hemostatic potential of green compared to standard-color plasma. Read More

View Article and Full-Text PDF

Severe COVID-19 Infection Management in a Patient with Mild Haemophilia-A Case Report.

Hematol Rep 2022 Mar 30;14(2):103-107. Epub 2022 Mar 30.

Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.

Patients with haemophilia present a significant challenge when admitted into the intensive care unit. To prevent haemorrhagic complications related to the infection or due to invasive procedures factor (F) VIII/IX must be substituted. As thromboembolic complications are frequent among critically ill COVID-19 patients, thromboprophylaxis is also applied to patients with haemophilia. Read More

View Article and Full-Text PDF

Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia.

J Pers Med 2022 Mar 23;12(4). Epub 2022 Mar 23.

Department of Internal Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.

Cardiovascular disease in hemophiliacs has an increasing prevalence due to the aging of this population. Hemophiliacs are perceived as having a high bleeding risk due to the coagulation factor VIII/IX deficiency, but it is currently acknowledged that they also have an important ischemic risk. The treatment of atrial fibrillation (AF) is particularly challenging since it usually requires anticoagulant treatment. Read More

View Article and Full-Text PDF

rs6092 Variant Is Related to Plasma Coagulation Proteins in Patients with Severe COVID-19 from a Tertiary Care Hospital.

Biology (Basel) 2022 Apr 14;11(4). Epub 2022 Apr 14.

HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.

An impaired coagulation process has been described in patients with severe or critical coronavirus disease (COVID-19). Nevertheless, the implication of coagulation-related genes has not been explored. We aimed to evaluate the impact of rs6025 and rs6092 on invasive mechanical ventilation (IMV) requirement and the levels of coagulation proteins among patients with severe COVID-19. Read More

View Article and Full-Text PDF

HO-1 Upregulation by Kaempferol via ROS-Dependent Nrf2-ARE Cascade Attenuates Lipopolysaccharide-Mediated Intercellular Cell Adhesion Molecule-1 Expression in Human Pulmonary Alveolar Epithelial Cells.

Antioxidants (Basel) 2022 Apr 14;11(4). Epub 2022 Apr 14.

Department of Pharmacology, College of Medicine, China Medical University, Taichung 40402, Taiwan.

Lung inflammation is a pivotal event in the pathogenesis of acute lung injury. Heme oxygenase-1 (HO-1) is a key antioxidant enzyme that could be induced by kaempferol (KPR) and exerts anti-inflammatory effects. However, the molecular mechanisms of KPR-mediated HO-1 expression and its effects on inflammatory responses remain unknown in human pulmonary alveolar epithelial cells (HPAEpiCs). Read More

View Article and Full-Text PDF

Bitiscetin-3, a Novel C-Type Lectin-like Protein Cloned from the Venom Gland of the Viper , Induces Platelet Agglutination and Inhibits Binding of Von Willebrand Factor to Collagen.

Toxins (Basel) 2022 Mar 25;14(4). Epub 2022 Mar 25.

Graduate School of Medical Sciences, Fujita Health University, 1-98 Kutsukake-cho, Toyoake 470-1192, Japan.

Bitiscetin-1 (aka bitiscetin) and bitiscetin-2 are C-type lectin-like proteins purified from the venom of (puff adder). They bind to von Willebrand factor (VWF) and-at least bitiscetin-1-induce platelet agglutination via enhancement of VWF binding to platelet glycoprotein Ib (GPIb). Bitiscetin-1 and -2 bind the VWF A1 and A3 domains, respectively. Read More

View Article and Full-Text PDF

[Corrigendum] miR‑647 and miR‑1914 promote cancer progression equivalently by downregulating nuclear factor IX in colorectal cancer.

Mol Med Rep 2022 Jun 21;25(6). Epub 2022 Apr 21.

Department of Digestive Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.

Subsequently to the publication of this paper, an interested reader drew to the authors' attention that, in the scratch‑wound assays shown in Fig. 3A on p. 8195, the data shown for the '0 h/NC' and '0 h/miR‑1914 antagomir' data panels appeared to be strikingly similar, such that they may have been derived from the same original source. Read More

View Article and Full-Text PDF

Development of a sandwich enzyme-linked immunosorbent assay (ELISA) to quantify γ-glutamyl-carboxylated clotting factor IX and assess redox susceptibility of anticoagulant chemicals.

J Vet Med Sci 2022 Apr 20. Epub 2022 Apr 20.

Laboratory of Toxicology, School of Veterinary Medicine, Kitasato University.

Anticoagulant chemicals (ACCs) such as warfarin are widely used in medical applications as well as for their rodenticide properties. Their efficacy is greatly influenced by polymorphisms in the gene encoding vitamin K epoxide reductase (VKOR). Evaluation of the activity of ACCs toward VKOR variants is essential to determine their proper use. Read More

View Article and Full-Text PDF